How has Sutro Biopharma's deferred revenue, net of current portion changed year-over-year?

Sutro Biopharma's deferred revenue, net of current portion decreased by 85.6% year-over-year, from $8.57M to $1.23M.

What is the long-term trend for Sutro Biopharma's deferred revenue, net of current portion?

Over 4 years (2020 to 2025), Sutro Biopharma's deferred revenue, net of current portion has grown at a -24.1% compound annual growth rate (CAGR), from $6.1M to $2.03M.

Sutro Biopharma STRO Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

RegenxbioRGNX

——

SchrodingerSDGR

——

CytomX TherapeuticsCTMX

——

Recursion Pharmaceuticals, Inc.RXRX

——

BridgeBio PharmaBBIO

——

Arrowhead ResearchARWR

——

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's deferred revenue, net of current portion?: Sutro Biopharma (STRO) reported deferred revenue, net of current portion of $1.23M in Q1 2026.
How has Sutro Biopharma's deferred revenue, net of current portion changed year-over-year?: Sutro Biopharma's deferred revenue, net of current portion decreased by 85.6% year-over-year, from $8.57M to $1.23M.
What is the long-term trend for Sutro Biopharma's deferred revenue, net of current portion?: Over 4 years (2020 to 2025), Sutro Biopharma's deferred revenue, net of current portion has grown at a -24.1% compound annual growth rate (CAGR), from $6.1M to $2.03M.